My guess is they were invited to speak privately at the meeting with a pharmaceutical company and its executive leaders and decided as long as they were attending to try to schedule meetings with other interest parties.

It would be a great venue to meet directly with BP leaders, especially those from overseas. Face to face negotiations can be very effective.

"Innovation Pharmaceuticals plans to leverage the conference to continue to build and strengthen business development relationships across its clinical pipeline..."

“It’s an exciting time for the Company as we work toward solidifying Pharma partnerships—advancing ongoing licensing efforts that are already well underway, as well as generating interest among other potential partners,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Both Brilacidin and Kevetrin are Platform drug candidates with multiple therapeutic applications given unique mechanisms of action and properties. We feel strongly that these drug candidates hold tremendous treatment potential for improving the lives of countless patients and look forward to continuing to evaluate them in clinical trials.”

Good luck,Farrell